For Spain’s billionaire Grifols family, which turned a blood-collection business into one of the world’s largest medical ...

Grifols (NASDAQ:GRFS) has commenced discussions with banks to refinance its bonds due in 2025, Bloomberg News reported, a day ...

The embattled Spanish drugmaker Grifols SA is in talks with banks to refinance about €1.4 billion ($1.48 billion) in bonds ...

On Wednesday, Grifols SA (NASDAQ:GRFS) said it ended discussions with Brookfield Capital Partners (UK) Limited about a ...

Grifols rejects Brookfield’s €10.5/share offer, signaling undervaluation. Read why GRFS stock is a strong "Buy" despite the ...

Canadian investment fund Brookfield said Wednesday it has dropped its bid for Spanish pharmaceutical firm Grifols following ...

With Spanish plasma specialist Grifols turning down a potential multi-billion-dollar takeover bid, it’s likely back to the ...

The Board of Directors of Grifols (GRFS) announced the termination of discussions with Brookfield Capital Partners UK regarding a ...

Brookfield Asset Management has walked away from an acquisition of Spanish healthcare group Grifols after months of negotiations, sending shares in the short seller target down almost 13 per cent.

The Spanish pharmaceutical company said it considered Brookfield’s offer of 10.50 euros a share undervalued the company and ...

Brookfield withdrew its bid for the Spanish pharmaceutical company following a deadlock between the two side over price ...

Grifols SA’s board of directors said it won’t recommend that shareholders accept Brookfield Asset Management’s indicative ...